Investors & Media

BRISBANE, Calif.--(BUSINESS WIRE)--Apr. 27, 2021-- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced upcoming data presentations at the 24^th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) being held May 11-14, 2021, in a virtual format.

“Our zinc finger technology has shown the versatility to have broad applications across a diverse range of therapeutic areas and the upcoming presentations at ASGCT will focus on one area of particularly high unmet need: neurodegenerative diseases,” said Jason Fontenot, Ph.D., Chief Scientific Officer at Sangamo. “These abstracts show the potential of zinc finger protein transcription factors to modulate expression of targeted genes in ALS and Parkinson’s disease. We are encouraged that these early results demonstrate the specificity, potency and potential of our transcriptional regulation technology as an impactful genomic medicine approach for these difficult-to-treat conditions. We look forward to continuing our research.”

ASGCT Annual Meeting Presentations:

• Selective repression of C9ORF72 repeat expansion-containing sense and antisense transcripts for the treatment of amyotrophic lateral sclerosis (ALS) – Abstract #577
  Poster Presentation – Tuesday, May 11; 8:00-10:00 a.m. ET
• Alpha-synuclein repression using zinc finger protein transcription factors – a novel therapeutic approach for the treatment of Parkinson’s disease – Abstract #539
  Poster Presentation – Tuesday, May 11; 8:00-10:00 a.m. ET

All abstracts for the ASGCT Annual Meeting are available on ASGCT’s website.

About Sangamo Therapeutics 

Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, cell therapy, and genome engineering. For more information about Sangamo, visit www.sangamo.com.

Forward-Looking Statements

This press release contains forward-looking statements based on our current expectations. These forward-looking statements include, without limitation, statements relating to the potential to use zinc finger technology, including zinc finger protein transcription factors, to develop safe, effective and durable therapies. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Our actual results may differ materially and adversely from those expressed. Factors that could cause actual results to differ include, but are not limited to, the research development process, including the results of clinical trials; the unpredictable regulatory approval process for product candidates; the manufacturing of products and product candidates; the commercialization of approved products; and the potential for technological developments that obviate technologies used by Sangamo. There can be no assurance that we will be able to develop and obtain the necessary regulatory approvals for commercially viable products. These risks and uncertainties are described more fully in our Annual Report on Form 10-K for the year ended December 31, 2020 as filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and we undertake no duty to update such information except as required under applicable laws.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210427006019/en/

Investor Relations & Media Inquiries
Aron Feingold
628.252.7494
afeingold@sangamo.com

Source: Sangamo Therapeutics, Inc.